Envigo / Inotiv

The Cumberland facility operated continuously since the 1960s under a succession of corporate owners — each inheriting the same dogs, the same buildings, and the same problems. The lineage traces through five distinct corporate identities over six decades.

The central accelerant for federal action was a months-long undercover investigation by PETA in 2021 at the Cumberland facility. An on-the-ground eyewitness documented systemic welfare problems and specific incidents that advocacy materials argue would not have been visible from paper compliance alone. PETA filed a complaint to USDA in fall 2021 (described as October 2021 in multiple sources).

The investigation overlapped with escalating federal inspections. USDA inspections ran in July 2021, October 2021, November 2021, and March 2022. PETA's public narrative included allegations of concealment behavior — staff being warned to misrepresent practices — and graphic descriptions of euthanasia and veterinary failures.

A key named figure is Dawn Marie Gau, identified as the attending veterinarian during the investigation period. In June 2025, PETA reported Gau was indicted by a grand jury on 17 misdemeanor cruelty-to-animals counts connected to this matter.

The criminal Information documented systematic failures at the on-site wastewater treatment plant, with animal waste slurry and human waste discharging into Maxey Mill Creek (connecting to Deep Creek and the James River). Specific documented discharges included:

U.S. Senators Mark Warner and Tim Kaine (both D-VA) sent a March 31, 2022 letter to USDA APHIS Administrator Kevin Shea urging “aggressive enforcement actions” against Envigo, referencing repeated failures and pointing to USDA's enforcement authorities. Their press statement described “continued horrific mistreatment of dogs and puppies at Virginia facility.”

Virginia's Attorney General participated directly in the criminal resolution, reflecting state-federal coordination with signature pages and acknowledgments involving the Commonwealth of Virginia in the plea package. The DOJ's June 2024 press release emphasized multi-level governmental involvement, highlighting combined animal welfare and environmental enforcement in a single corporate resolution.

PETA attributes the passage of multiple Virginia “beagle bills” to advocacy momentum following the Cumberland case. The bipartisan Congressional attention helped build political conditions for the FDA Modernization Act 2.0 (signed December 2022), which removed the 1938 animal testing mandate — though direct legislative linkage to this specific case is not confirmed in congressional record evidence reviewed.

Inotiv describes the Cumberland operation as a “shuttered legacy Envigo canine breeding facility.” The corporate resolution includes heightened standards of care across all Inotiv entities and a compliance monitor — not just closure of a single property. A federal securities class action (In Re Inotiv Inc Securities Litigation, No. 4:2022cv00045, N.D. Indiana) survived a motion to dismiss in March 2024, with a preliminary settlement of $8.75 million resolving investor claims about allegedly false/misleading statements connected to the Envigo acquisition.

As of March 2026, Inotiv's share price is approximately $0.32 per share — micro-cap scale, down from the period when the company valued Envigo at a $545M enterprise value. Corporate communications show sustained financing pressure, including credit agreement amendments providing covenant relief through the quarter ending June 30, 2025, in the context of liquidity and optimization efforts. Inotiv issued a public “Statement of Contrition” alongside the plea announcement.

The closure of Cumberland removed approximately 5,000 dogs from the US purpose-bred supply chain, forcing research establishments and intermediaries to source animals differently. A UK research-communication organization acknowledged broader research community concerns following the closure and noted the facility's role in supplying establishments, supporting the reality of downstream supply disruption. Combined with Ridglan's settlement (license surrender by July 2026), Marshall BioResources is becoming the near-monopoly supplier of purpose-bred beagles in the United States. The Cumberland site itself was sold in June 2024.